Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

被引:15
|
作者
Lee, Dae Hyun [1 ,2 ]
Kumar, Abhishek [3 ]
Mohammed, Turab [4 ,5 ]
Peres, Lauren C. [6 ]
Alsina, Melissa [5 ]
Bachmeier, Christina
Blue, Brandon J. [5 ]
Brayer, Jason
Chandrasekhar, Sanjay [2 ]
Cruz, Ariel Grajales [5 ]
De Avila, Gabe
Elmariah, Hany [4 ]
Faramand, Rawan [4 ]
Freeman, Ciara [4 ]
Jain, Michael [4 ]
Khadka, Sushmita [4 ]
Khimani, Farhad [4 ]
Liu, Hien [4 ]
Nishihori, Taiga [4 ]
Oswald, Laura B. [1 ,7 ]
Puglianini, Omar A. Castaneda [4 ]
Shain, Kenneth H. [5 ]
Smith, Eric [4 ]
Baz, Rachid C. [5 ]
Locke, Frederick L. [4 ]
Oliveira, Guilherme H. [1 ,2 ]
Alomar, Mohammed [1 ,2 ]
Hansen, Doris K. [4 ]
机构
[1] Univ South Florida Morsani, Coll Med, Div Cardiovasc Med, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Cardiooncol, Tampa, FL USA
[3] Univ South Florida Morsani, Dept Internal Med, Coll Med, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunoth, Tampa, FL 33612 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA
关键词
T-CELL THERAPY; CARDIOVASCULAR EVENTS; ADULTS;
D O I
10.1182/bloodadvances.2023009766
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence of cardiac events associated with ide-cel remains unclear. This was a retrospective single-center observational study of patients treated with ide-cel for RRMM. We included all consecutive patients who received standard-of-care ide-cel treatment at least 1-month follow-up. Baseline clinical risk factors, safety profile, and responses were examined based on the development of a cardiac event. A total of 78 patients were treated with ide-cel, and 11 patients (14.1%) developed cardiac events: heart failure (5.1%), atrial fibrillation (10.3%), nonsustained ventricular tachycardia (3.8%), and cardiovascular death (1.3%). Only 11 of the 78 patients had repeat echocardiogram. Baseline risk factors associated with the development of cardiac events included being female sex and having poor performance status, & lambda; light-chain disease, and advanced Revised International Staging System stage. Baseline cardiac characteristics were not associated with cardiac events. During index hospitalization after CAR-T, higher-grade (& GE;grade 2) cytokine release syndrome (CRS) and immune cell-associated neurologic syndrome were associated with cardiac events. In multivariable analyses, the hazard ratio for the association of the presence of cardiac events with overall survival (OS) was 2.66 and progression-free survival (PFS) was 1.98. Ide-cel CAR-T for RRMM was associated with similar cardiac events as other types of CAR-T. Worse baseline performance status and higher-grade CRS and neurotoxicity were associated with cardiac events after BCMA-directed CAR-T-cell therapy. Our results suggest that the presence of cardiac events may confer worse PFS or OS; although because of the small sample size, the power to detect an association was limited.
引用
收藏
页码:4247 / 4257
页数:11
相关论文
共 50 条
  • [41] Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
    Lin, Yi
    Raje, Noopur S.
    Berdeja, Jesus G.
    Siegel, David S.
    Jagannath, Sundar
    Madduri, Deepu
    Liedtke, Michaela
    Rosenblatt, Jacalyn
    Maus, Marcela V.
    Massaro, Monica
    Petrocca, Fabio
    Yeri, Ashish
    Finney, Olivia
    Caia, Andrea
    Yang, Zhihong
    Martin, Nathan
    Campbell, Timothy B.
    Rytlewski, Julie
    Fuller, Jaymes
    Hege, Kristen
    Munshi, Nikhil C.
    Kochenderfer, James N.
    NATURE MEDICINE, 2023, 29 (09) : 2286 - +
  • [42] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
    Minakata, Daisuke
    Ishida, Tadao
    Ando, Kiyoshi
    Suzuki, Rikio
    Tanaka, Junji
    Hagiwara, Shotaro
    Ananthakrishnan, Revathi
    Kuwayama, Shigeki
    Nishio, Mitsufumi
    Kanda, Yoshinobu
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (05) : 729 - 737
  • [43] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
    Daisuke Minakata
    Tadao Ishida
    Kiyoshi Ando
    Rikio Suzuki
    Junji Tanaka
    Shotaro Hagiwara
    Revathi Ananthakrishnan
    Shigeki Kuwayama
    Mitsufumi Nishio
    Yoshinobu Kanda
    Kenshi Suzuki
    International Journal of Hematology, 2023, 117 : 729 - 737
  • [44] Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/ Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation
    John, Lukas
    Sauer, Sandra
    Hegenbart, Ute
    Dreger, Peter
    Hundemer, Michael
    Mueller-Tidow, Carsten
    Schmitt, Anita
    Schmitt, Michael
    Raab, Marc S.
    Schoenland, Stefan O.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (10): : 609.e1 - 609.e6
  • [45] Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed and refractory multiple myeloma: real-world experience
    Hansen, Doris
    Sidana, Surbhi
    Peres, Lauren
    Leitzinger, Christelle Colin
    Shune, Leyla
    Shrewsbury, Alexandria
    Gonzalez, Rebecca
    Sborov, Douglas
    Wagner, Charlotte
    Hashmi, Hamza
    Kocoglu, Mehmet
    Atrash, Shebli
    Simmons, Gary
    Kalariya, Nilesh
    Ferreri, Christopher
    Afrough, Aimaz
    Kansagra, Ankit
    Voorhees, Peter
    Baz, Rachid
    Khouri, Jack
    Alsina, Melissa
    McGuirk, Joseph
    Locke, Frederick
    Patel, Krina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S2 - S3
  • [46] Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.
    Zanwar, Saurabh
    Sidana, Surbhi
    Shune, Leyla
    Alexis, Omar
    Puglianini, Castaneda
    Pasvolsky, Oren
    Gonzalez, Rebecca
    Dima, Danai
    Afrough, Aimaz
    Kaur, Gurbakhash
    Davis, James A.
    Herr, Megan
    Hashmi, Hamza
    Forsberg, Peter A.
    Sborov, Douglas W.
    Richard, Shambavi
    Khouri, Jack
    Lin, Yi
    Patel, Krina K.
    Kumar, Shaji
    Hansen, Doris K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Bendamustine Lymphodepletion (LD) Prior to Idecabtagene Vicleucel (Ide-cel) Is Associated with Inferior Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
    Ravi, Gayathri
    Bal, Susan
    Godby, Kelly
    Giri, Smith
    Hebert, Courtney
    Parekh, Binita
    Steele, JoAnn
    Brown, Jessica
    Langley, Kathy
    Costa, Luciano
    BLOOD, 2023, 142
  • [48] Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study
    Rodriguez-Otero, Paula
    San-Miguel, Jesus F.
    Anderson, Larry D., Jr.
    Lonial, Sagar
    Truppel-Hartmann, Anna
    Sanford, Jill
    Rowe, Everton
    Campbell, Timothy B.
    Munshi, Nikhil C.
    BLOOD, 2021, 138
  • [49] Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
    Sidana, Surbhi
    Peres, Lauren C.
    Hashmi, Hamza
    Hosoya, Hitomi
    Ferreri, Christopher J.
    Atrash, Shebli
    Khouri, Jack
    Voorhees, Peter M.
    Dima, Danai
    Simmons, Gary
    Kalariya, Nilesh
    Hovanky, Vanna
    Bharadwaj, Sushma
    Arai, Sally
    Miklos, David B.
    Wagner, Charlotte B.
    Davis, James
    Sborov, Douglas W.
    Nishihori, Taiga
    Alsina, Melissa
    Locke, Frederick L.
    Gonzalez, Rebecca
    Kocoglu, M. Hakan
    Sannareddy, Aishwarya
    Afrough, Aimaz
    McGuirk, Joseph P.
    Shune, Leyla O.
    Patel, Krina
    Hansen, Doris K.
    BLOOD, 2022, 140 : 10377 - 10379
  • [50] Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma
    Kansagra, Ankit
    Lin, Yi
    Berdeja, Jesus G.
    Shah, Nina
    Oriol, Albert
    Yakoub-Agha, Ibrahim
    Einsele, Hermann
    Rambaldi, Alessandro
    Truppel-Hartmann, Anna
    Rowe, Everton
    Wang, Julie
    Agarwal, Amit
    Campbell, Timothy B.
    Lonial, Sagar
    BLOOD, 2020, 136